Equities Analysts Set Expectations for SAGE Q1 Earnings

Sage Therapeutics, Inc. (NASDAQ:SAGE) – Stock analysts at Wedbush issued their Q1 2026 earnings per share estimates for shares of Sage Therapeutics in a research note issued on Wednesday, April 16th. Wedbush analyst L. Chico forecasts that the biopharmaceutical company will earn ($0.75) per share for the quarter. Wedbush has a “Neutral” rating and a $6.00 price target on the stock. The consensus estimate for Sage Therapeutics’ current full-year earnings is ($3.52) per share. Wedbush also issued estimates for Sage Therapeutics’ Q2 2026 earnings at ($0.72) EPS, Q3 2026 earnings at ($0.69) EPS and Q4 2026 earnings at ($0.65) EPS.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%.

Other equities research analysts have also recently issued research reports about the company. Bank of America started coverage on Sage Therapeutics in a report on Tuesday, March 11th. They set an “underperform” rating and a $5.00 price objective for the company. Needham & Company LLC restated a “hold” rating on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Piper Sandler lowered their price objective on Sage Therapeutics from $26.00 to $9.00 and set an “overweight” rating on the stock in a research report on Thursday, January 2nd. Scotiabank reduced their target price on shares of Sage Therapeutics from $14.00 to $12.00 and set a “sector outperform” rating for the company in a research report on Wednesday, February 12th. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $12.00 price target (down from $14.00) on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Three research analysts have rated the stock with a sell rating, fifteen have given a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $8.81.

Sage Therapeutics Stock Performance

Shares of SAGE opened at $7.43 on Thursday. The firm has a market cap of $456.80 million, a P/E ratio of -1.13 and a beta of 0.48. Sage Therapeutics has a 52 week low of $4.62 and a 52 week high of $14.97. The firm’s 50-day simple moving average is $7.47 and its 200 day simple moving average is $6.72.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. State Street Corp boosted its holdings in shares of Sage Therapeutics by 18.2% in the 3rd quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company’s stock valued at $21,127,000 after purchasing an additional 451,377 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Sage Therapeutics by 0.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company’s stock worth $8,975,000 after buying an additional 3,757 shares during the last quarter. SG Americas Securities LLC boosted its stake in Sage Therapeutics by 57.7% in the fourth quarter. SG Americas Securities LLC now owns 22,498 shares of the biopharmaceutical company’s stock valued at $122,000 after buying an additional 8,228 shares in the last quarter. Inspire Investing LLC boosted its stake in Sage Therapeutics by 30.4% in the fourth quarter. Inspire Investing LLC now owns 75,313 shares of the biopharmaceutical company’s stock valued at $409,000 after buying an additional 17,541 shares in the last quarter. Finally, Empowered Funds LLC bought a new position in Sage Therapeutics in the fourth quarter valued at about $91,000. 99.22% of the stock is owned by institutional investors.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.